GSWM
ALT icon

Golden State Wealth Management’s Altimmune ALT Stock Holding History

Golden State Wealth Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-975
Closed -$3K – 228
2020
Q1 		$3K Buy
+975
New +$2.24K ﹤0.01% 803

Other funds holding ALT

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Golden State Wealth Management's ALT Position: Q2 2020 in Review

Golden State Wealth Management sold out of Altimmune (ALT) in Q2 2020, closing a stake of 975 shares — an estimated $3K sold.

Golden State Wealth Management first reported a position in ALT in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 57 funds tracked by Wall St. Rank hold ALT as of Q2 2020.

  • Golden State Wealth Management reported no remaining Altimmune position as of Q2 2020 after selling out during the quarter.
  • Golden State Wealth Management sold 975 Altimmune shares in Q2 2020, an estimated $3K.
  • Golden State Wealth Management first reported a position in Altimmune in Q1 2020 and held it in 1 quarter.
  • Golden State Wealth Management's Altimmune position peaked at $3K in Q1 2020.
  • 57 funds tracked by Wall St. Rank held Altimmune as of Q2 2020.

Based on Golden State Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.